🇺🇸

US SEC Filing Intelligence

· monthly

US Pre-Market SEC Filings Roundup — September 04, 2026

Overnight SEC filings from September 3-4, 2026, reveal a market bifurcated between high-conviction insider selling in growth/biotech names and significant corporate actions (M&A, spin-offs, restructurings). The most critical development is the FDA approval of Ionis Pharmaceuticals' ZANVASTRO for Alexander disease, a landmark event for an ultra-rare disorder, though offset by a mixed financial picture. A wave of insider selling, particularly at Natera, Spyre Therapeutics, and Takeda, signals potential near-term tops in these high-flying names. Activist pressure is building at TransAct Technologies, while corporate restructuring dominates headlines with Flex's spin-off and The Trade Desk's 15% workforce reduction. The IPO litigation settlement at Rent the Runway and the de-registration of RE/MAX highlight ongoing post-IPO and M&A fallout. Overall, the data suggests a cautious tone from corporate insiders, offset by significant strategic catalysts in biotech and energy.

39 high priority 11 medium 50 total filings
· daily

HHS & Healthcare Contracts Intelligence — September 03, 2026

The single $290.9 million firm-fixed-price contract awarded to Walgreens by the CDC under the ICATT program represents a fully obligated civilian health services win with high near-term revenue visibility through May 2025. This is a material, competitively awarded deal that underscores the CDC’s continued investment in specialized medical support infrastructure. However, the contract’s fixed-price structure carries medium execution risk, and the fully obligated nature means no further upside from option exercises. The bullish signal is strong at 7/10, but investors should monitor Walgreens’ ability to manage costs under this pricing model and track CDC budget allocations for the ICATT program in FY2025-2026 as a key renewal catalyst.

1 total filings
· daily

New Federal Contractors — September 03, 2026

This digest covers a single, large civilian contract awarded to Walgreens Boots Alliance by the Department of Health and Human Services (CDC) valued at $290.9 million. The contract is fully obligated and outlayed, providing high near-term revenue visibility for Walgreens through May 2025 under the ICATT program. The award was competitive and firm-fixed-price, offering margin upside potential but also execution risk. The key risk is the lack of defense exposure and the medium-term uncertainty around contract renewal or follow-on awards after May 2025.

1 total filings
· daily

Significant Contract Modifications ($10M+) — September 03, 2026

The sole contract in this period is a $290.9 million firm-fixed-price award from the CDC to Walgreens for specialized medical support under the ICATT program, representing 100% civilian agency spending. This fully obligated contract provides high near-term revenue visibility for Walgreens Boots Alliance through May 2025, with an estimated annual revenue contribution of $96.9 million. The award was won via full and open competition, signaling Walgreens' competitive strength in the public health services market. However, the fixed-price structure introduces execution risk, and the contract's concentration in a single program (ICATT) creates dependency on CDC budget priorities. Investors should monitor CDC's FY2025/FY2026 budget allocations and any follow-on award announcements for sustained growth.

1 total filings
· daily

Contract Deobligations Alert — September 03, 2026

This single-contract digest reveals a $290.9 million civilian award from the Department of Health and Human Services (CDC) to Walgreens, with zero defense-related activity. The contract, fully obligated and outlayed under the ICATT program, provides near-term revenue visibility for Walgreens Boots Alliance through May 2025. The bullish signal is tempered by medium execution risk from the firm-fixed-price structure and the absence of defense exposure, which limits sector-wide implications. Key watch items include Walgreens' cost management on this fixed-price contract and CDC budget allocations for FY2025-2026.

1 total filings
· daily

Contract Option Exercises — September 03, 2026

This digest covers a single, large civilian contract option exercise totaling $290.9 million, awarded to Walgreens Boots Alliance by the Department of Health and Human Services (CDC). The entire obligation is civilian, with no defense-related awards in the period. The highest-conviction signal is a bullish revenue visibility for Walgreens through May 2025, driven by a fully obligated firm-fixed-price contract for the ICATT program. However, the key risk is the fixed-price structure, which creates execution risk if costs overrun, and the medium-term uncertainty regarding contract renewal after May 2025.

1 total filings
· daily

All HHS Contracts — September 03, 2026

This single-contract digest covers a $290.9 million civilian award from the CDC to Walgreens under the ICATT program, with no defense-related content. The fully obligated, firm-fixed-price contract provides high near-term revenue visibility for Walgreens Boots Alliance through May 2025, but execution risk is material given the fixed-price structure on a service-intensive program. The dominant theme is stable civilian healthcare spending, specifically CDC's continued funding for specialized medical support services, with no cross-contract patterns or concentration beyond this single award. The highest-conviction signal is bullish for Walgreens due to full obligation and competitive win, though fixed-price risk and program dependency are key watch items.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — September 03, 2026

This digest covers a single $290.9 million civilian mega-contract awarded to Walgreens Boots Alliance by the CDC under the ICATT program, representing 100% non-defense spending. The contract is fully obligated and outlayed, providing high near-term revenue visibility through May 2025, but its firm-fixed-price structure introduces medium execution risk. The highest-conviction signal is the bullish revenue certainty for Walgreens, though the absence of defense exposure and the single-contract concentration limit broader sector implications. Key watch items include CDC budget allocations for ICATT in FY2025-2026 and potential competitor wins that could signal market share shifts.

1 total filings
· daily

High-Value Federal Grants ($5M+) — September 03, 2026

The sole contract in this period is a $290.9 million firm-fixed-price award from the CDC to Walgreens for specialized medical support under the ICATT program, marking a fully civilian (non-defense) transaction. This single-award stream shows a high-conviction bullish signal for Walgreens Boots Alliance, providing near-term revenue visibility through May 2025. The contract's full obligation and outlay reduce budget risk, but the fixed-price structure introduces execution risk, and the program's future depends on CDC budget allocations. Investors should monitor Walgreens' Q2 2025 earnings for renewal signals and track ICATT funding in FY2025-2026 appropriations.

1 total filings
· daily

General Federal Contracts — September 03, 2026

This digest covers a single, large civilian contract totaling $290.9 million, awarded to Walgreens Boots Alliance by the Department of Health and Human Services (CDC). The contract, which is fully obligated and outlayed, provides high near-term revenue visibility for Walgreens through May 2025 under the ICATT program. The highest-conviction signal is the bullish revenue certainty from this fully funded, firm-fixed-price award, though the fixed-price structure introduces medium execution risk. A key watch item is the potential for a follow-on contract or re-compete, which will be critical for sustaining this revenue stream beyond the current performance period.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — September 03, 2026

The 11 filings for the S&P 500 Technology sector reveal a period of significant insider activity, dominated by large-scale, pre-planned stock sales and tax-related share withholdings at key companies. The most critical development is NVIDIA's $11.9 billion acquisition of Hugging Face, a high-materiality, mixed-sentiment deal that signals a major strategic pivot toward open-source AI platforms, though it carries regulatory risk. Insider selling patterns are pronounced, with Lam Research's Senior VP selling $8.01M and Intuit's CEO having $4.45M in shares withheld for taxes, while Apple and Palantir directors executed smaller 10b5-1 sales. The overall sentiment across filings is negative to neutral, with no bullish signals. A key portfolio-level theme is the lack of forward-looking guidance or capital allocation changes in these filings, making the insider activity and the transformative NVIDIA deal the primary drivers of actionable intelligence. The concentrated insider selling, particularly at Lam Research and Intuit, warrants close monitoring for potential sector-wide headwinds in hardware and software.

8 high priority 3 medium 11 total filings
· daily

Nasdaq 100 Stocks SEC Filings — September 03, 2026

The 26 filings from NASDAQ-100 constituents reveal a mixed landscape dominated by insider transactions, a major M&A deal, and a notable executive transition. A significant cluster of insider selling, particularly at CoreWeave and Lam Research, signals potential caution among top executives, while a wave of tax-related share withholdings at Intuit and PayPal suggests routine compensation management rather than bearish sentiment. The most impactful development is NVIDIA's $11.9 billion acquisition of Hugging Face, a bold bet on open-source AI that carries regulatory and geopolitical risks. T-Mobile's CFO succession plan is a positive, orderly leadership transition. Overall, the data points to a market where capital is being actively reallocated, with AI infrastructure spending driving both opportunity and risk, while insider activity warrants close monitoring for further conviction signals.

16 high priority 10 medium 26 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — September 03, 2026

The September 3, 2026, batch of 50 filings reveals a market dominated by passive institutional adjustments and technical corrections, with several high-conviction activist and insider moves creating distinct opportunities. A notable theme is the administrative realignment at The Vanguard Group, which generated six low-materiality filings correcting issuer CIKs and reporting zero beneficial ownership post-internal restructuring, creating noise but no actionable signals. Conversely, high-conviction activist activity is concentrated in small-cap and micro-cap names, with Gareth Nichol acquiring a 20.17% stake in Dynaresource and a group led by Bastion Trading launching an activist campaign against SkyAI (formerly Sharps Technology), demanding board change. The most significant capital event is the consummation of AbbVie's acquisition of Apogee Therapeutics at $135.11 per share, providing a clear exit for Fairmount Funds. Insider selling plans are notable at Paycom Software, where Chad Richison authorized a 10b5-1 plan to sell up to 1.09 million shares, while Ryan Cohen's passive reduction in GameStop due to dilution signals no change in insider conviction. Sector-wise, the data shows a concentration of activist interest in struggling small-cap industrials and cannabis-adjacent companies, while passive institutional flows remain steady in ETFs and mid-cap value names. The overall portfolio-level pattern suggests a bifurcated market: large passive flows are administrative, while alpha is being generated through targeted activist campaigns in distressed or underperforming small caps.

18 high priority 32 medium 50 total filings
· daily

S&P 500 Financials Sector SEC Filings — September 03, 2026

The 13 filings for the S&P 500 Financials stream, dated September 3, 2026, reveal a concentrated wave of insider selling, particularly among senior executives at Marsh & McLennan (CEO sold $3.14M), Mastercard (CBO sold $1.91M), and Coinbase (Director sold $602K), all executed under Rule 10b5-1 plans, suggesting pre-planned diversification rather than immediate concern. However, the sheer volume and timing of these sales, alongside a 10% owner sale at AFLAC ($1M), create a cautious sentiment across the sector. In contrast, Truist Financial's CEO was awarded a substantial 351,941 restricted stock units, signaling strong long-term alignment and a bullish outlook from the board. Notably, three Robinhood filings were unparseable, limiting insights from that high-growth fintech. The lone operational filing, a securitization 8-K from a Morgan Stanley/Bank of America trust, points to continued activity in the commercial mortgage-backed securities market, though it is a routine transaction. Overall, the period's data highlights a divergence between insider profit-taking at established firms and significant equity-based incentive grants at a major regional bank, with no period-over-period financial trends or forward guidance available in the filings to provide broader context.

12 high priority 1 medium 13 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — September 03, 2026

The three filings from the S&P 500 Consumer Staples sector (Dollar General, Church & Dwight, McCormick) are dominated by insider transactions, but with no period-over-period comparisons, forward-looking guidance, or capital allocation data available. The most notable signal is a significant insider sale by Dollar General's EVP & Chief People Officer, Kathleen Reardon, who sold $733K worth of stock at $131.33, a transaction that warrants scrutiny given the company's recent operational challenges. In contrast, Church & Dwight and McCormick show only routine, low-materiality insider transactions (tax withholdings and phantom stock awards), suggesting no management concern or conviction. The lack of any guidance changes, M&A activity, or financial ratio trends across the three filings limits the depth of sector-wide themes, but the Dollar General sale stands out as a potential bearish signal in the consumer staples space, where margin pressure and shifting consumer behavior remain key risks.

3 high priority 3 total filings
· daily

S&P 500 Industrials Sector SEC Filings — September 03, 2026

The latest batch of 9 filings from the S&P 500 Industrials stream reveals a sector-wide focus on long-term executive compensation and retention, with 7 of 9 filings involving restricted stock unit (RSU) awards to key officers. This pattern, concentrated at UPS, 3M, and Eaton, signals a strong push to align management with multi-year performance goals, particularly in digital transformation and international operations. A notable outlier is a bullish insider purchase at Honeywell Aerospace, where a director invested nearly $1M, signaling strong conviction in the aerospace cycle. Conversely, two filings from ADP show mandatory tax-withholding sales by a director and a CMO, which are routine but still represent insider liquidity events. The absence of any forward-looking guidance changes, period-over-period financial comparisons, or capital allocation announcements (dividends, buybacks) in this batch suggests these filings are primarily governance-related, with no immediate shifts in corporate strategy. The key takeaway is a stable, retention-focused environment in industrials, with a single high-conviction buy signal from Honeywell that warrants attention.

9 high priority 9 total filings
· daily

US Material Events SEC 8-K Filings — September 03, 2026

This Material Events Monitor digest covers 50 filings, predominantly 8-Ks, revealing a market heavily engaged in strategic transactions and leadership transitions. A clear theme is the aggressive pursuit of growth through M&A, with notable deals in financial services (Equity Bancshares acquiring Lincoln Bancorp), industrial distribution (Hillman Solutions buying Kanebridge), and specialty materials (Apogee Enterprises acquiring GroGlass). Concurrently, the SPAC market remains active but faces significant headwinds, with several entities (Andretti Acquisition Corp. II, Wintergreen Acquisition Corp.) securing short-term extensions and non-redemption agreements to avoid liquidation, highlighting a challenging environment for de-SPAC transactions. Leadership changes are widespread, with several high-profile CFO and C-suite appointments (T-Mobile, Albemarle, Passage BIO) signaling strategic pivots or succession planning. Financially, the digest shows a bifurcated market: high-growth software (Guidewire) and logistics (Radiant) companies are investing in leadership and capacity, while pre-revenue biotechs (NextCure) and distressed entities (SunPower, Faraday Future) are taking defensive actions like lease terminations and warrant cancellations to preserve capital. The overall sentiment is cautiously optimistic, with a focus on execution risk and the ability of companies to navigate integration and funding challenges.

50 high priority 50 total filings
· daily

Insider Trading Pulse — September 03, 2026

The September 3, 2026 insider trading digest reveals a market dominated by routine equity awards and tax-withholding transactions, with a few high-conviction signals standing out. The most significant bullish development is the Chairman & CEO of Amrize Ltd purchasing $638K in stock, signaling strong insider confidence. Conversely, notable insider selling at Heritage Insurance Holdings (CAO sold $312K under a 10b5-1 plan) and EUROSEAS (CAO sold $75K) warrants caution. The period is also marked by a wave of director and executive equity grants at STRATTEC SECURITY, HONDA MOTOR, and NOVAGOLD RESOURCES, which are largely neutral but indicate ongoing compensation alignment. A cluster of tax-withholding sales at HMH Holding Inc. across multiple C-suite executives suggests a routine post-vesting event rather than a bearish signal. Overall, the digest points to a bifurcated market where selective insider buying in specific names contrasts with broader, non-directional insider activity.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — September 03, 2026

This batch of 19 filings from Dow 30 constituents is dominated by insider transactions, with a clear divergence between buying and selling. Honeywell Aerospace saw a significant director purchase of nearly $1M at $156, a strong bullish signal. In contrast, several top executives at Disney, Amazon, and Apple executed pre-planned sales, which are less alarming but still notable. The most material event is NVIDIA's $11.9 billion acquisition of Hugging Face, a high-stakes bet on open-source AI that carries regulatory risk. The most striking pattern is a massive, coordinated equity award and tax-withholding event at NIKE, where the entire C-suite and CEO received substantial stock and options, signaling strong long-term alignment despite the stock trading near $39. This suggests the board is incentivizing leadership to drive a turnaround. 3M also made smaller equity awards to key digital and HR executives.

15 high priority 4 medium 19 total filings